Surgical and oncological outcomes in patients with preoperative PSA >20 ng/ml undergoing robot-assisted radical prostatectomy

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 2091-2096

  Zugor, Vahudin ^a   Witt, Jorn H ^a   Heidenreich, Axel ^b   Porres, Daniel ^b   Labanaris, Apostolos P ^a  

^a St Antonius Medical Center   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Oncological outcomes; Prostate cancer; PSA value >20 ng ml; Robot assisted laparoscopic radical prostatectomy; Surgical outcomes

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER STAGING; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; ROBOT ASSISTED RADICAL PROSTATECTOMY; TREATMENT OUTCOME;

ADULT; AGED; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; POSTOPERATIVE COMPLICATIONS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; ROBOTICS;

EID: 84861516965     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277: 1445-1451, 1997. (Pubitemid 27208886)
2. Hugosson J, Aus G, Lilja H, Lodding P and Pihl CG: Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100: 1397-1405, 2004. (Pubitemid 38366842)
3. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M and Edwards BK: SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; pp. 1975-2004, 2007.
4. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, Wolff J and Zattoni F: European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 48: 546-551, 2005. (Pubitemid 41278578)
5. Amling CL, Bergstralh EJ, Blute ML, Slezak JM and Zincke H: Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165: 1146-1151, 2001. (Pubitemid 32210224)
6. Freedland SJ, Partin AW, Humphreys EB, Mangold LA and Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer 109: 1273-1278, 2007. (Pubitemid 46466553)
7. Ward JF, Slezak JM, Blute ML, Bergstralh EJ and Zincke H: Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95: 751-756, 2005. (Pubitemid 40547200)
8. Carver BS, Bianco FJ, Jr, Scardino PT and Eastham JA: Longterm outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176: 564-568, 2006. (Pubitemid 43927886)
9. Ficarra V, Cavalleri S, Novara G, Aragona M and Artibani W: Evidence from robot-assisted laparoscopic radical prostatectomy: a systematic review. Eur Urol 51: 45-56, 2007. (Pubitemid 44821522)
10. Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J and Van Poppel H: Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 55: 1037-1063, 2009.
11. Witt JH, Zugor V, Wagner C, Shuette A and Labanaris AP: Robot-Assisted Radical Prostatectomy, Laparoscopy - An Interdisciplinary Approach, Ivo Meinhold-Heerlein (ed.). ISBN: 978-953-307-299-9, InTech, Available from: http://www.intechopen.com/articles/show/title/robot-assisted- radicalprostatectomy, 2011.
12. Dindo D, Demartines N and Clavien PA: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240: 205-213, 2004. (Pubitemid 38963009)
13. Zwergel U, Suttmann H, Schroeder T, Siemer S, Wullich B, Kamradt J, Lehmann J and Stoeckle M: Outcome of Prostate Cancer Patients with Initial PSA ≥20 ng/ml Undergoing Radical Prostatectomy. Eur Urol 52: 1058-1066, 2007. (Pubitemid 47337032)
14. Inman BA, Davies JD, Rangel LJ, Bergstralh EJ, Kwon ED, Blute ML, Karnes RJ and Leibovich BC: Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level ≥50 ng/mL. Cancer 113(7): 1544-1551, 2008.
15. Nguyen K, Eltz S, Drouin SJ, Comperat E, Audenet F, Renard-Penna R, Bitker MO, Chartier-Kastler E, Richard F, Cussenot O and Rouprêt M: Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. World J Urol 27(5): 653-658, 2009.
16. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A and Coleman CN: Pretreatment nomogram for prostatespecific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17: 168-172, 1999. (Pubitemid 29022390)
17. Han M, Partin AW, Pound CR, Epstein JI and Walsh PC: Longterm biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28: 555-565, 2001. (Pubitemid 32916759)
18. May M, Gunia S, Helke C, Führer S, Hoschke B, Fahlenkamp D, Vogler H and Siegsmund M: How far is the preoperative Kattan nomogram applicable for the prediction of recurrence after prostatectomy in patients presenting with PSA levels of more than 20 ng/ml? A validation study. Urol Int 77: 222-226, 2006. (Pubitemid 44567811)
19. Vis AN, Schröder FH and van der Kwast TH: The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 50: 258-265, 2006. (Pubitemid 44038060)
20. Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL and Zincke H: Anatomic site-specific positive margins in organ confined prostate cancer and its impact on outcome after radical prostatectomy. Urology 50: 733-739, 1997. (Pubitemid 27494995)
21. Aydin H, Tsuzuki T, Hernandez D, Walsh PC, Partin AW and Epstein JI: Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology 64: 551-555, 2004. (Pubitemid 39200756)